View Older Stories View More Recent Stories

Jan 10, 2017 03:30AM Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer
Jan 9, 2017 04:00PM Kite Pharma (KITE) Enters Strategic Partnership With Daiichi Sankyo for KTE-C19 in Japan
Jan 9, 2017 04:00PM Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan
Jan 5, 2017 08:30AM Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors
Jan 4, 2017 08:30AM Kite Pharma to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 3, 2017 08:35AM Kite Pharma (KITE) IND Submitted to Initiate Phase 1 Trial of KITE-718
Jan 3, 2017 08:30AM Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6
Dec 19, 2016 08:35AM Kite Pharma (KITE) Sucessfully Defends Roberts Patent, to Appeal USPTO Decision on Patent on Select CD28 CAR-T Products
Dec 19, 2016 08:30AM Kite Pharma Announces Successful Defense of Roberts Patent and Intent to Appeal U.S. Patent and Trademark Office Decision on a Narrow Patent Focused on Select CD28 CAR-T Products
Dec 13, 2016 08:32AM Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks
Dec 13, 2016 08:30AM Kite Pharma and Vitruvian Networks Enter Strategic Partnership to Develop Best-In-Class Logistics and Data Analytics Software for Engineered T-cell Therapies at Commercial Scale
Dec 12, 2016 08:36AM Kite Pharma (KITE) T-Cell Therapy Targeting Mutant KRAS Research Published in NEJM
Dec 12, 2016 08:30AM Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
Dec 6, 2016 10:33AM Kite Pharma (KITE) Presents Data from ZUMA-1 Trial in NHL; Primary Endpoint of ORR Met
Dec 6, 2016 10:30AM Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Societ
Dec 5, 2016 06:16AM Kite Pharma (KITE) Announces Strong Remission Results from Two KTE-C19 Phase 1s
Dec 4, 2016 10:30PM Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Ag
Dec 4, 2016 09:00PM Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapse
Dec 1, 2016 08:30AM Kite Pharma Appoints Jian Irish, PhD as Senior Vice President of Supply Chain
Nov 23, 2016 09:24AM Pre-Open Stock Movers 11/23: (MDGS) (VEEV) (BLXT) Higher; (JUNO) (LLY) (URBN) Lower (more...)
Nov 21, 2016 09:20AM Kite Pharma (KITE) Will Make Late-Breaking Presentation of KTE-C19 ZUMA-1 Trial Data at ASH 2016
Nov 21, 2016 09:19AM Kite Pharma to Present Interim Results from the ZUMA-1 Pivotal Trial of KTE-C19 in a Late-Breaking Session at the 2016 American Society of Hematology Annual Meeting
Nov 9, 2016 09:00AM Kite Pharma Reports Third Quarter 2016 Financial Results
Nov 3, 2016 09:58AM Kite Pharma (KITE) Will Present KTE-C19 Data in PMBCL, TFL at ASH 2016
Nov 3, 2016 09:28AM Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 Pivotal Trial in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (
Nov 2, 2016 08:30AM Kite Pharma to Report Third Quarter 2016 Financial Results on November 9, 2016
Oct 28, 2016 08:30AM Kite Pharma to Present at November 2016 Investor Conferences
Oct 19, 2016 08:42AM Kite Pharma (KITE) Announces Details on CAR/TCR Pipeline, KTE-C19 Launch Outlook
Oct 19, 2016 08:41AM Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day
Oct 13, 2016 08:30AM Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations and Advance the Company’s CAR/TCR Therapy Portfolio in the Region
Oct 11, 2016 08:30AM Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Research and Development, and KTE-C19 Launch Readiness
Oct 7, 2016 11:00AM Kite Pharma (KITE) Offers Updated 12-Month Follow-Up Data from ZUMA-1 Phase 1 at ESMO
Oct 7, 2016 10:59AM Kite Pharma Presents 12-Month Follow-Up Data from ZUMA-1 Phase 1 at the European Society for Medical Oncology (ESMO) Annual Congress
Oct 6, 2016 08:31AM Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)
Oct 6, 2016 08:30AM Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Sep 29, 2016 04:05PM Kite Pharma Names Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations
Sep 26, 2016 04:02PM Kite Pharma (KITE) Announces Positive Topline Data from KTE-C19 ZUMA-1 Study in Aggressive NHL
Sep 26, 2016 04:01PM Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)
Sep 20, 2016 04:09PM Kite Pharma (KITE) Reports Exclusive License with NIH for TCR Product Candidates
Sep 20, 2016 04:05PM Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
Aug 31, 2016 04:05PM Kite Pharma to Participate in September 2016 Investor Conferences
Aug 19, 2016 08:00AM Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
Aug 8, 2016 04:05PM Kite Pharma Reports Second Quarter 2016 Financial Results
Aug 3, 2016 04:05PM Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference
Aug 1, 2016 04:05PM Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016
Jul 27, 2016 04:35PM Kite Pharma (KITE) Enters Licensing Agreement with NIH for Anti-CD19 CAR Product
Jul 27, 2016 04:05PM Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
Jul 25, 2016 04:06PM Kite Pharma (KITE) Licenses Off-the-Shelf Allogeneic T-Cell Therapies Technology
Jul 25, 2016 04:05PM Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
Jul 11, 2016 09:31AM Pre-Open Stock Movers 07/11: (BLFS) (SGNT) (IMPV) Higher; (CJES) (TWTR) (CHTR) Lower (more...)
View More Recent Stories View Older Stories